Low muscle mass is associated with efficacy of biologics in Crohn's disease

doi:10.1016/j.clnu.2024.09.003

科研成果详情

题名	Low muscle mass is associated with efficacy of biologics in Crohn's disease
作者	Fang, Ye1,2; Fang, Luyan1,2; Ye, Mengqian2,3; Jiang, Hanyue 4; Long, Xinyu 4; Zhang, Haoxuan 4; Zhang, Qianqian 4; Lin, Daopo1,2; Shao, Xiaoxiao1,2
发表日期	2024-10
发表期刊	Clinical Nutrition 影响因子和分区
语种	英语
原始文献类型	Article
关键词	Crohn's disease Low muscle mass Infliximab Ustekinumab Drug efficacy
其他关键词	ANTI-TNF THERAPY ; INFLAMMATORY-BOWEL-DISEASE ; BODY-COMPOSITION ; INDEX
摘要	Background: Low muscle mass (LMM) can be a frequent complication in Crohn's disease (CD). We attempted to explore the effect of LMM on the efficacy of biologics in patients with CD. Methods: The retrospective cohort study included moderate-to-severe CD patients treated with infliximab or ustekinumab, and appendicitis patients as control. The skeletal muscle area (SMA) of L3 was assessed to evaluate the patients' muscle mass. After propensity score matching, the impact of LMM on drug efficacy was assessed in CD patients. Results: A total of 269 patients with CD and 172 appendicitis patients were included. The CD group had lower skeletal muscle density and BMI, and a higher risk of developing LMM than the control group. BMI (OR = 0.48, p < 0.001) and previous use of biologics (OR = 2.94, p = 0.019) were found to be independently associated with LMM. LMM was found to be associated with a decrease in clinical response (at weeks 8-14), clinical remission (at weeks 8-14, 24-30 and 52) and biochemical remission (at week 52). At weeks 24-30 and 52, LMM was independently associated with loss of response (LOR). We found LMM could be a predictor of lower clinical remission at week 30, lower clinical remission at week 52 and a higher LOR rate at week 30 in infliximab. While in ustekinumab, LMM was associated with lower endoscopic remission at week 24, biochemical remission at week 52 and a higher LOR rate at weeks 24 and 52. Conclusions: The prevalence of LMM was higher in the CD group compared to the control group. For CD patients with LMM, the efficacy of infliximab and ustekinumab was relatively poor in both the shortterm and long-term. (c) 2024 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism. All rights are reserved, including those for text and data mining, AI training, and similar technologies.
资助项目	Zhejiang Provincial Natural Science Foundation [LY23H030004]; Chinese Medicine Research Program of Zhejiang Province [2021428317, 2021439649]; Wenzhou Science and Technology Bureau Foundation [Y20220031]; Lin He Academician Workstation Program [19331101, 19331104]
出版者	CHURCHILL LIVINGSTONE
ISSN	0261-5614
EISSN	1532-1983
卷号	43 期号:10 页码:2354-2363
DOI	10.1016/j.clnu.2024.09.003
页数	10
WOS类目	Nutrition & Dietetics
WOS研究方向	Nutrition & Dietetics
WOS记录号	WOS:001315009900001
收录类别	SCIE ; SCOPUS ; PUBMED
URL	查看原文
PubMed ID	39265296
SCOPUSEID	2-s2.0-85203508283
通讯作者地址	[Lin, Daopo;Shao, Xiaoxiao]Wenzhou Med Univ, Affiliated Hosp 2, Dept Gastroenterol, Wenzhou, Peoples R China. ; [Lin, Daopo;Shao, Xiaoxiao]Wenzhou Med Univ, Yuying Childrens Hosp, Wenzhou, Peoples R China.
Scopus学科分类	Nutrition and Dietetics;Critical Care and Intensive Care Medicine
SCOPUS_ID	SCOPUS_ID:85203508283
引用统计
文献类型	期刊论文
条目标识符	https://kms.wmu.edu.cn/handle/3ETUA0LF/218734
专题	附属第二医院附属第二医院_神经内科附属第二医院_消化内科第二临床医学院、附属第二医院、育英儿童医院
通讯作者	Lin, Daopo; Shao, Xiaoxiao
作者单位	1.Wenzhou Med Univ, Affiliated Hosp 2, Dept Gastroenterol, Wenzhou, Peoples R China; 2.Wenzhou Med Univ, Yuying Childrens Hosp, Wenzhou, Peoples R China; 3.Wenzhou Med Univ, Affiliated Hosp 2, Dept Neurol, Wenzhou, Peoples R China; 4.Wenzhou Med Univ, Sch Med 2, Wenzhou, Peoples R China
第一作者单位	附属第二医院; 第二临床医学院，附属第二医院、育英儿童医院; 消化内科
通讯作者单位	附属第二医院; 第二临床医学院，附属第二医院、育英儿童医院; 消化内科
第一作者的第一单位	附属第二医院
推荐引用方式 GB/T 7714	Fang, Ye,Fang, Luyan,Ye, Mengqian,et al. Low muscle mass is associated with efficacy of biologics in Crohn's disease[J]. Clinical Nutrition,2024,43(10):2354-2363.
APA	Fang, Ye., Fang, Luyan., Ye, Mengqian., Jiang, Hanyue., Long, Xinyu., ... & Shao, Xiaoxiao. (2024). Low muscle mass is associated with efficacy of biologics in Crohn's disease. Clinical Nutrition, 43(10), 2354-2363.
MLA	Fang, Ye,et al."Low muscle mass is associated with efficacy of biologics in Crohn's disease".Clinical Nutrition 43.10(2024):2354-2363.